AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$TLX

Smith Darren Charlton purchased $20K of TLX

Smith Darren Charlton (Group Chief Financial Officer) purchased 2,071 shares of Telix Pharmaceuticals Ltd (TLX) at $9.66 on 2026-09-07.

Original reporting
SEC EDGAR · Smith Darren Charlton
Published Sep 14, 2026, 11:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TLX
Neutral
high confidence
Mentioned
$TLX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TLXNeutralLow
01

Why it matters

The CFO's purchase modestly raises his ownership, but the transaction size is too small to affect market perception significantly.

02

Market read

Insider purchase is a routine filing with limited trading relevance.

03

What to watch

Potential upcoming FDA filing or trial data could make this purchase more meaningful.

Relevance 4/10Novelty 4/10Timing: filing released post‑market on 2026‑09‑14

Background

Form 4 disclosures provide the first public record of insider transactions.

Company-level read

Ticker impact

$TLXNeutralHigh confidence
Context

CFO Smith Darren Charlton bought 2,071 shares of Telix Pharmaceuticals for $19,997, increasing his stake to 13,992 shares.

Expected impact

Minimal short‑term price movement expected.

Evidence & confidence

Purchase size (~$20K) is negligible relative to market cap; likely no immediate trading signal.

Market effects

Sector

No broader sector impact; insider activity is isolated to Telix.

Regional

Limited to U.S. biotech investors.

Global

None

Counterpoint

What could challenge this read

Even small insider buys can precede positive news; monitor for upcoming clinical updates.

Key entities

  • Company
    Telix Pharmaceuticals Ltd

    Biopharma company listed on Nasdaq (TLX).

  • Insider
    Smith Darren Charlton

    Group Chief Financial Officer of Telix.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TLX insider trading history →

Related articles

OCT 6
$TLXMedAI 8/10

First U.S. Patient Receives Telix's Newly Approved Brain Cancer Imaging Drug

Telix Pharmaceuticals (TLX) announced the first U.S. patient received Pixclara, its FDA-approved brain cancer imaging drug. Administered at Indiana University Health and University Hospitals, Pixclara helps differentiate glioma progression from treatment effects. TLX partnered with PharmaLogic for U.S. distribution. The stock closed at $10.88, up 3.13%, and was at $10.98 in pre-market trading.

rttnews.com2 min
OCT 6
$TLXHigh

Telix Pharmaceuticals: First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara (floretyrosine F 18)

Telix Pharmaceuticals announced the first U.S. patients have been dosed with Pixclara, its FDA-approved brain cancer imaging drug. Pixclara is the only FDA-approved radiopharmaceutical for glioma imaging. The drug is now commercially available, with PharmaLogic Holdings supplying doses. Pixclara helps differentiate recurrent or progressive glioma from treatment-related changes, addressing a significant unmet medical need.

marketscreener.com3 min
OCT 2
$LLYMedAI 8/10

Rx Rundown: Eli Lilly, AstraZeneca, United Immunity and more

Sanofi & Regeneron expanded their immunology partnership for up to $8B. Novo Nordisk acquired rights to a drug from Hengrui Pharma for up to $2.6B. Telix Pharmaceuticals to acquire ITM Isotope for up to $2.35B. Merck licensed a cancer drug from SciBrunch for up to $2.13B. Genentech partnered with Earendil Labs for up to $1.5B. GSK acquired a hepatic program from Wave Life Sciences. Lundbeck may acquire Xeris Biopharma.

mmm-online.com3 min
SEP 30
$TLXLowAI 8/10

Telix Pharmaceuticals Limited gets BiPASS Fast Track

Telix Pharmaceuticals (ASX:TLX, NASDAQ:TLX) received FDA BiPASS Fast Track status for its gallium-68 PSMA PET imaging agents, Illuccix and Gozellix, for investigational use before prostate biopsy. The company completed a 350-patient Phase 3 study on Sept. 2 and plans to submit a new drug application. Shares traded at A$15.93, down 1.36%, at 12:03 p.m. AEST in Sydney.

mugglehead.com2 min